Related Experiment Video
Updated: Jun 23, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Brain-derived neurotrophic factor: focus on the pathogenesis of multiple myeloma and the development of
Karolina Łuczkowska1, Piotr Kulig1, Bartłomiej Baumert2
1Department of General Pathology, Pomeranian Medical University, Szczecin, Poland.
Abstract:
For many years, intensive research has been carried out on the in-depth understanding of the pathogenesis of multiple myeloma (MM). Nevertheless, the multifactorial nature of the disease, the development of drug resistance, and the side effects of therapy, make it difficult to effectively treat patients. One of the many factors involved in the pathogenesis of MM is brain-derived neurotrophic factor (BDNF). This factor is widely described as a neuroregenerative and neuroprotective agent, but it also regulates non-neuronal cell functions, such as proliferation, apoptosis, and viability. Therefore, BDNF appears to be a good therapeutic target in MM. On the other hand, its decreased concentration during treatment closely correlates with the development of peripheral neuropathy (PN). BDNF dualism requires a detailed understanding of its action on individual molecular mechanisms. Perhaps the optimization of the BDNF level will contribute to the improvement of MM treatment and the reduction of chemotherapy side effects.
Insights
Brain-derived neurotrophic factor (BDNF) plays a dual role in multiple myeloma (MM) pathogenesis and treatment. Understanding BDNF
Area of Science:
- Oncology
- Neuroscience
- Molecular Biology
Background:
- Multiple myeloma (MM) presents complex challenges due to its multifactorial nature, drug resistance, and treatment side effects.
- Brain-derived neurotrophic factor (BDNF) is implicated in MM pathogenesis, influencing cell proliferation, apoptosis, and viability.
- Decreased BDNF levels during MM treatment correlate with peripheral neuropathy (PN), highlighting its complex role.
Purpose of the Study:
- To explore the dual role of BDNF in multiple myeloma (MM).
- To understand the molecular mechanisms underlying BDNF's action in MM and its relation to peripheral neuropathy (PN).
- To evaluate BDNF as a potential therapeutic target for improving MM treatment and reducing chemotherapy side effects.
Main Methods:
- Literature review and analysis of existing research on BDNF in MM.
- Investigation of molecular pathways affected by BDNF in MM cells.
- Correlation analysis between BDNF levels, MM progression, and PN development.
Main Results:
- BDNF exhibits a dual role, potentially promoting MM progression while also being linked to neuroprotection.
- Reduced BDNF levels are associated with the development of PN in MM patients undergoing treatment.
- The precise molecular functions of BDNF in MM require further elucidation.
Conclusions:
- BDNF represents a potential therapeutic target in MM, but its complex actions need careful consideration.
- Optimizing BDNF levels may improve MM treatment outcomes and mitigate chemotherapy-induced PN.
- Further research into BDNF's molecular mechanisms is crucial for therapeutic development.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
